This product is a luciferase encoding oncolytic vaccinia virus, which is based on VACV-WR with K3L deleted. Binding of CXCL10 to CXCR3 results in pleiotropic effects, including stimulation of monocytes, natural killer and T-cell migration, and modulation of adhesion molecule expression. The deletion of K3L and CXCL10 expression could enhance the immune activity. This product can be used in oncolytic virotherapy research and vaccinie application.
Specifications
Family
Poxviridae
Species
Vaccinia virus
Serotype
Western Reserve
Backbone
VACV-WR(ΔK3L)
Backbone Background
VACV-WR strain derived from Wyeth through passaging in mice and shown high tumor selectivity and strong oncolytic effect in mouse models.The engineered VACV-WR could further enhance the immune activity and the efficacy of cancer therapies.
Gene Modification
ΔK3L
Promoter
pSE
Transgene
luciferase
Type of Transgene
Reporter gene
Related Target/Protein
Luciferase
Capsid Modification
None
Titer
>1*10^8 PFU
Related Diseases
Breast cancer, Prostate cancer, Colon cancer, Cancer vaccine
Transgene
Alternative Names
luciferase, Fluc
Information
Introduction
Luciferase is a generic term for the class of oxidative enzymes that produce bioluminescence, and is usually distinguished from a photoprotein. Luciferases are widely used in biotechnology, for microscopy and as reporter genes, for many of the same applications as fluorescent proteins. However, unlike fluorescent proteins, luciferases do not require an external light source, but do require addition of luciferin, the consumable substrate.
Customer Reviews and Q&As
There are currently no customer reviews or questions for luciferase-encoding Oncolytic Vaccinia Virus Western Reserve (ΔK3L), pSE-(luciferase) (RepOV-0047WQ). Click the button below to contact us or submit your feedback about this product.
All products and services are for Research Use Only. Not For Clinical Use.